COL17A1 and Pruritus: Indeed, with the number of available therapeutic options rapidly increasing, clinicians should focus on identifying comorbidities, clinical variables (e.g., bullous vs. non-bullous phenotypes and pruritus intensity), laboratory [e.g., neutrophil-rich vs. eosinophil-rich infiltrates at histopathology, or the intensity of complement deposition at direct immunofluorescence (DIF)] and serological findings (e.g., titer of IgG and IgE antibodies against BP180/BP230) or molecular factors (e.g., cytokine concentration) which may influence therapy-response and decision-making.